Patents by Inventor Bruce A. Hay

Bruce A. Hay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12213468
    Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: February 4, 2025
    Assignee: California Institute of Technology
    Inventors: Bruce A. Hay, Omar S. Akbari, Anna B. Buchman
  • Publication number: 20250032620
    Abstract: Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: May 13, 2024
    Publication date: January 30, 2025
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Publication number: 20240425845
    Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.
    Type: Application
    Filed: September 3, 2024
    Publication date: December 26, 2024
    Inventors: Bruce A. Hay, Georg Oberhofer, Tobin William Ivy
  • Patent number: 12157883
    Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 3, 2024
    Assignee: California Institute of Technology
    Inventors: Bruce A Hay, Georg Oberhofer, Tobin William Ivy
  • Publication number: 20240376212
    Abstract: A chemical compound and a method for treating cancer in a mammal. The chemical compound is a first Markusch structure of A-L1-PEG1-L2-PEG2-CL-X, a second Markusch structure of A-L1-PEG1-N3, or a third Markusch structure of A-L1-PEG1-OMethyl. A-L1-PEG is a targeting structure configured for targeting ?v integrins in cancer cells and does not include a standard multivalent nitrogen moiety. A is a structure that includes a standard carboxylic acid moiety. L1 and L2 are linking structures. PEG1 and PEG2 are polyethylene glycol structures having n2 and n4 monomer units, respectively, where n2 is in range of 5-72, n4 is in range of 0-67, and n2+n4 is in range of 20-72. CL is a cleavage linker linked to PEG2. X is a chemotherapy linked to CL. N3 is —N?N?N. In one embodiment, the method uses the first Markusch structure to treat the cancer.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 14, 2024
    Inventors: Shaker A. Mousa, Bruce A. Hay
  • Publication number: 20240366772
    Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: June 24, 2024
    Publication date: November 7, 2024
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Publication number: 20240344081
    Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.
    Type: Application
    Filed: March 20, 2024
    Publication date: October 17, 2024
    Inventors: Bruce A. Hay, Georg Oberhofer, Tobin William Ivy
  • Patent number: 12059470
    Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: May 8, 2023
    Date of Patent: August 13, 2024
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Patent number: 11965172
    Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: April 23, 2024
    Assignee: California Institute of Technology
    Inventors: Bruce A. Hay, Georg Oberhofer, Tobin William Ivy
  • Publication number: 20240123028
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 18, 2024
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Publication number: 20240108732
    Abstract: Formulated and/or co-formulated nanocarriers comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the nanocarriers are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a nanocarrier (e.g., LNP or SLNP) to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: March 10, 2023
    Publication date: April 4, 2024
    Inventors: David Stover, Dhruba Bharali, Bruce A HAY, Tahmineh Safale
  • Publication number: 20240050575
    Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: July 10, 2023
    Publication date: February 15, 2024
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Patent number: 11896646
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: February 13, 2024
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Patent number: 11833209
    Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: December 5, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Publication number: 20230372442
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: May 4, 2023
    Publication date: November 23, 2023
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Patent number: 11801304
    Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: October 31, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Publication number: 20230277621
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 7, 2023
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Patent number: 11744874
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: September 5, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Publication number: 20230270819
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Application
    Filed: October 14, 2022
    Publication date: August 31, 2023
    Inventors: David Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
  • Patent number: 11723888
    Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further comprise an additional substituent also conjugated to the polymer. The compounds/compositions may demonstrate antiangiogenic effect and efficacy against conditions, particularly cancers.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: August 15, 2023
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Bruce A. Hay, Ozlem Ozen Karakus